Pub Date : 2021-01-01DOI: 10.11669/cpj.2021.13.013
Y. Liu, X. Xiang, W. Huang, B. Wang, Z. Hu, X. Yu
OBJECTIVE: To acquire the knowledge of quality control performance through carrying out proficiency Testing Schemes (PTS) nationwide. METHODS: National Institutes for Food and Drug Control(NIFDC) schemed three PTS to evaluate the testing competence of participants from the aspects of safety and stability of vaccine products and pseudotyped virus-based neutralization assay, pseudotyped virus based neutralization assay(PBNA), which takes as a hand of COVID-19 vaccine development. RESULTS: Eighty-nine participants took part in the three PTS and the satisfaction rate stated as 96.9%, 96.4% and 76.0%. CONCLUSION: The testing ability and quality control performance of Official Medical Control Laboratories (OMCL), manufacturers and research institutes are acceptable. The testing results of sterile testing and aluminum assay of aluminum adjuvanted vaccine can be assured well, while the ability of PBNA needs to be improved by some manufacturers.
{"title":"Results and Discussion on National Vaccine Proficiency Testing Schemes in 2020","authors":"Y. Liu, X. Xiang, W. Huang, B. Wang, Z. Hu, X. Yu","doi":"10.11669/cpj.2021.13.013","DOIUrl":"https://doi.org/10.11669/cpj.2021.13.013","url":null,"abstract":"OBJECTIVE: To acquire the knowledge of quality control performance through carrying out proficiency Testing Schemes (PTS) nationwide. METHODS: National Institutes for Food and Drug Control(NIFDC) schemed three PTS to evaluate the testing competence of participants from the aspects of safety and stability of vaccine products and pseudotyped virus-based neutralization assay, pseudotyped virus based neutralization assay(PBNA), which takes as a hand of COVID-19 vaccine development. RESULTS: Eighty-nine participants took part in the three PTS and the satisfaction rate stated as 96.9%, 96.4% and 76.0%. CONCLUSION: The testing ability and quality control performance of Official Medical Control Laboratories (OMCL), manufacturers and research institutes are acceptable. The testing results of sterile testing and aluminum assay of aluminum adjuvanted vaccine can be assured well, while the ability of PBNA needs to be improved by some manufacturers.","PeriodicalId":22409,"journal":{"name":"The Chinese Pharmaceutical Journal","volume":"43 1","pages":"1099-1103"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84289949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.11669/cpj.2021.14.011
T. Huang, S. Han, X. Guan, Luwen Shi
OBJECTIVE: To explore the impact of timely inclusion of medical insurance on the use of high-quality domestic innovative drugs, using the domestic innovative drug, icotinib, as an example. METHODS Province X and province Z with large difference on the timing to include icotinib in medical insurance were selected as sample provinces to compare and analyze the price, volume and expenditure changes of three targeted drugs (gefitinib, erlotinib and icotinib) for non-small cell lung cancer (NSCLC), using the sample hospital procurement data covering two provinces from 2013 to 2018 in the China Medical Economic Information Network (CMEI) database. RESULTS In two sample provinces, icotinib's daily cost had been the lowest among three sample drug's for a long time. Province Z has included icotinib in the basic health insurance since 2013. After that, the market shares of icotinib's volume and expenditure had increased rapidly from 0, and remained at about 85% for a long period of time, occupying the dominant position in province Z's market. However, province X has not included icotinib until 2016. The highest market share of icotinib's volume was only 8% in province X's market. There was little difference of sample drugs' daily cost between two provinces. After the national health insurance negotiation, the daily cost of sample drugs decreased significantly, with an overall decrease between 60% to 79%. By the second half of 2018, the daily cost of sample drugs was almost the same. CONCLUSION Timely inclusion of high-quality domestic innovative drugs in the scope of medical insurance reimbursement can greatly promote the use of high-quality domestic innovative drugs. Compared with foreign drugs with same indications, high-quality domestic innovative drugs can save money for patients, which will greatly benefit them.
{"title":"Case Study of Icotinib on The Impact of Domestic Innovative Drugs Timely Covered by Medical Insurance","authors":"T. Huang, S. Han, X. Guan, Luwen Shi","doi":"10.11669/cpj.2021.14.011","DOIUrl":"https://doi.org/10.11669/cpj.2021.14.011","url":null,"abstract":"OBJECTIVE: To explore the impact of timely inclusion of medical insurance on the use of high-quality domestic innovative drugs, using the domestic innovative drug, icotinib, as an example. METHODS Province X and province Z with large difference on the timing to include icotinib in medical insurance were selected as sample provinces to compare and analyze the price, volume and expenditure changes of three targeted drugs (gefitinib, erlotinib and icotinib) for non-small cell lung cancer (NSCLC), using the sample hospital procurement data covering two provinces from 2013 to 2018 in the China Medical Economic Information Network (CMEI) database. RESULTS In two sample provinces, icotinib's daily cost had been the lowest among three sample drug's for a long time. Province Z has included icotinib in the basic health insurance since 2013. After that, the market shares of icotinib's volume and expenditure had increased rapidly from 0, and remained at about 85% for a long period of time, occupying the dominant position in province Z's market. However, province X has not included icotinib until 2016. The highest market share of icotinib's volume was only 8% in province X's market. There was little difference of sample drugs' daily cost between two provinces. After the national health insurance negotiation, the daily cost of sample drugs decreased significantly, with an overall decrease between 60% to 79%. By the second half of 2018, the daily cost of sample drugs was almost the same. CONCLUSION Timely inclusion of high-quality domestic innovative drugs in the scope of medical insurance reimbursement can greatly promote the use of high-quality domestic innovative drugs. Compared with foreign drugs with same indications, high-quality domestic innovative drugs can save money for patients, which will greatly benefit them.","PeriodicalId":22409,"journal":{"name":"The Chinese Pharmaceutical Journal","volume":"7 1","pages":"1178-1181"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88151108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.11669/cpj.2021.12.002
F. Bu, J. Chen, N. Ding, Z. Jiao, X. Xiang
OBJECTIVE: To provide references for the selection of an appropriate statin and its dose adjustment in clinical practice when combined lopinavir/ritonavir (LPV/r) and statins. METHODS: Pharmacokinetic interactions between LPV/r and seven commonly used statins were reviewed by searching relevant domestic and foreign literatures. RESULTS AND CONCLUSIONS: Ritonavir is a potent time dependent inhibitor of cytochrome P450 3A4 (CYP3A4) and will greatly increase the plasma exposure of simvastatin and lovastatin, leading to the increasing risk of liver damage and rhabdomyolysis. Therefore, it is forbidden to use LPV/r together with these two statins. Whereas atorvastatin and rosuvastatin need to be used with caution and started at the lowest dose. No clinical data has been reported to support the relationship and extent of fluvastatin and LPV/r interactions, nor is there a dose recommendation for the combination. Moreover, LPV/r almost have no effect on the pharmacokinetic profiles of pravastatin and pitavastatin, so it is recommended to use pravastatin/pitavastatin with LPV/r in clinical practice.
{"title":"Research Progress of Pharmacokinetic Interactions between Lopinavir/Ritonavir and Statins","authors":"F. Bu, J. Chen, N. Ding, Z. Jiao, X. Xiang","doi":"10.11669/cpj.2021.12.002","DOIUrl":"https://doi.org/10.11669/cpj.2021.12.002","url":null,"abstract":"OBJECTIVE: To provide references for the selection of an appropriate statin and its dose adjustment in clinical practice when combined lopinavir/ritonavir (LPV/r) and statins. METHODS: Pharmacokinetic interactions between LPV/r and seven commonly used statins were reviewed by searching relevant domestic and foreign literatures. RESULTS AND CONCLUSIONS: Ritonavir is a potent time dependent inhibitor of cytochrome P450 3A4 (CYP3A4) and will greatly increase the plasma exposure of simvastatin and lovastatin, leading to the increasing risk of liver damage and rhabdomyolysis. Therefore, it is forbidden to use LPV/r together with these two statins. Whereas atorvastatin and rosuvastatin need to be used with caution and started at the lowest dose. No clinical data has been reported to support the relationship and extent of fluvastatin and LPV/r interactions, nor is there a dose recommendation for the combination. Moreover, LPV/r almost have no effect on the pharmacokinetic profiles of pravastatin and pitavastatin, so it is recommended to use pravastatin/pitavastatin with LPV/r in clinical practice.","PeriodicalId":22409,"journal":{"name":"The Chinese Pharmaceutical Journal","volume":"96 1","pages":"957-962"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80149381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-05-22DOI: 10.11669/CPJ.2020.10.004
Ning Pang, Li Yang, Rongsheng Zhao
OBJECTIVE: To use IFNα injection as inhalant for there is no proper dosage form for aerosol inhalation and evaluate the feasibility of IFN-α off-label use. METHODS: The clinical studies in SARS and MERS were reviewed to discuss the efficacy and safety of IFN-α application in COVID-19. Meanwhile, the features of aerosol inhalation, characteristics of IFN-α and related clinical researches were analyzed to argue the possibility of IFN-α aerosol inhalation. RESULTS: IFN-α seems to be effective in relieving early symptoms but likely invalid in reducing mortality of severe patients, however, the exact therapeutic effect calls for further clinical tests. Proper atomization of IFN-α injection won't reduce biological activity of the protein, but absorption and utilization of IFN-α in lung may be unsatisfactory for the lack of sorbefacient. More than that, ingredients in IFN-α injection may increase risk of adverse reaction. CONCLUSION: The aerosol inhalation of IFN-α injection should be fully evaluated on the side of patients. If there is a lack of proper atomization device or operation staff, subcutaneous injection of IFN-α may be a tentative administration.
{"title":"Evaluation of α-Interferon Applied in COVID-19 Therapy Regimen","authors":"Ning Pang, Li Yang, Rongsheng Zhao","doi":"10.11669/CPJ.2020.10.004","DOIUrl":"https://doi.org/10.11669/CPJ.2020.10.004","url":null,"abstract":"OBJECTIVE: To use IFNα injection as inhalant for there is no proper dosage form for aerosol inhalation and evaluate the feasibility of IFN-α off-label use. METHODS: The clinical studies in SARS and MERS were reviewed to discuss the efficacy and safety of IFN-α application in COVID-19. Meanwhile, the features of aerosol inhalation, characteristics of IFN-α and related clinical researches were analyzed to argue the possibility of IFN-α aerosol inhalation. RESULTS: IFN-α seems to be effective in relieving early symptoms but likely invalid in reducing mortality of severe patients, however, the exact therapeutic effect calls for further clinical tests. Proper atomization of IFN-α injection won't reduce biological activity of the protein, but absorption and utilization of IFN-α in lung may be unsatisfactory for the lack of sorbefacient. More than that, ingredients in IFN-α injection may increase risk of adverse reaction. CONCLUSION: The aerosol inhalation of IFN-α injection should be fully evaluated on the side of patients. If there is a lack of proper atomization device or operation staff, subcutaneous injection of IFN-α may be a tentative administration.","PeriodicalId":22409,"journal":{"name":"The Chinese Pharmaceutical Journal","volume":"32 37","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91404493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-05-08DOI: 10.11669/CPJ.2020.09.003
Yong Yang, Hao Shen, S. Zhao, Dong Wang, Hao Wang
OBJECTIVE: To investigate antiviral mechanism of bromhexine for the treatment of COVID-19. METHODS: Based on the existing literature, the infection pathways of new coronavirus(SARS-CoV-2) were systematically summarized by us, and used the SWISSDOCK molecular simulation method to carry out virtual screen systematically for key targets and marketed drugs. RESULTS: TMPRSS2/ACE2 pathway was found to be the most efficient and probably the major pathway for SARS-CoV-2 virus to infect the lung and other tissue by us. Bromhexine, an expectorant, can strongly inhibit TMPRSS2 protease (EC 50:0.75 μmol•L -1) in vitro. Bromhexine has few adverse effects and also has the beneficial effects of promoting the release and maintenance of endogenous active substances in the lung, alveolar function, and promoting sputum excretion, which is suitable for use together with other COVID19 medication and therapies. CONCLUSION: Bromhexine has a unique potential antiviral mechanism, and clinical research should be conducted to play its role in the prevention, treatment and prognosis of COVID19.
{"title":"Potential Mechanistic Investigation of Bromhexine for the Treatment of COVID-19","authors":"Yong Yang, Hao Shen, S. Zhao, Dong Wang, Hao Wang","doi":"10.11669/CPJ.2020.09.003","DOIUrl":"https://doi.org/10.11669/CPJ.2020.09.003","url":null,"abstract":"OBJECTIVE: To investigate antiviral mechanism of bromhexine for the treatment of COVID-19. METHODS: Based on the existing literature, the infection pathways of new coronavirus(SARS-CoV-2) were systematically summarized by us, and used the SWISSDOCK molecular simulation method to carry out virtual screen systematically for key targets and marketed drugs. RESULTS: TMPRSS2/ACE2 pathway was found to be the most efficient and probably the major pathway for SARS-CoV-2 virus to infect the lung and other tissue by us. Bromhexine, an expectorant, can strongly inhibit TMPRSS2 protease (EC 50:0.75 μmol•L -1) in vitro. Bromhexine has few adverse effects and also has the beneficial effects of promoting the release and maintenance of endogenous active substances in the lung, alveolar function, and promoting sputum excretion, which is suitable for use together with other COVID19 medication and therapies. CONCLUSION: Bromhexine has a unique potential antiviral mechanism, and clinical research should be conducted to play its role in the prevention, treatment and prognosis of COVID19.","PeriodicalId":22409,"journal":{"name":"The Chinese Pharmaceutical Journal","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89253767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-05-08DOI: 10.11669/CPJ.2020.09.004
Xi Hu, D. Hong, Hong Yang, D. Zheng, Q. Zhao
{"title":"Detection and Analysis of Safety Signals of Chloroquine Based Upon FDA Adverse Event Database","authors":"Xi Hu, D. Hong, Hong Yang, D. Zheng, Q. Zhao","doi":"10.11669/CPJ.2020.09.004","DOIUrl":"https://doi.org/10.11669/CPJ.2020.09.004","url":null,"abstract":"","PeriodicalId":22409,"journal":{"name":"The Chinese Pharmaceutical Journal","volume":"64 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86047621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-05-08DOI: 10.11669/CPJ.2020.09.006
Xiaolin Xu, Li Yang, Chen Chen, S. Zhai, Rongsheng Zhao
OBJECTIVE: To provide reference of donated drugs management for pharmaceutical departments during public health emergencies, so as to ensure the quality, safety and reasonable use of donated drugs. METHODS: Combined with the legal requirements and common problems of donated drugs, explore scientific and reasonable donated drug management principles, and establish donated drug management systems and processes. RESULTS: In the past, when medical institutions responded to major public health emergencies, there were some problems in the management of the demand, qualification and quality, validity, use, price, and surplus drugs of donated drugs. According to the requirements of the relevant laws, regulations and guidance on the characteristics, management, use and communication between donors and recipients of donated drugs, we established a scientific, reasonable and orderly management model, and clarified the management system, method and comprehensive management process. CONCLUSION: The problems, principles and models of donated drugs management were sorted out comprehensively, which is helpful to prevent and control of coronavirus disease 2019 (COVID-19).
{"title":"Management Strategy on Donated Medicines for COVID-19 Prevention and Control","authors":"Xiaolin Xu, Li Yang, Chen Chen, S. Zhai, Rongsheng Zhao","doi":"10.11669/CPJ.2020.09.006","DOIUrl":"https://doi.org/10.11669/CPJ.2020.09.006","url":null,"abstract":"OBJECTIVE: To provide reference of donated drugs management for pharmaceutical departments during public health emergencies, so as to ensure the quality, safety and reasonable use of donated drugs. METHODS: Combined with the legal requirements and common problems of donated drugs, explore scientific and reasonable donated drug management principles, and establish donated drug management systems and processes. RESULTS: In the past, when medical institutions responded to major public health emergencies, there were some problems in the management of the demand, qualification and quality, validity, use, price, and surplus drugs of donated drugs. According to the requirements of the relevant laws, regulations and guidance on the characteristics, management, use and communication between donors and recipients of donated drugs, we established a scientific, reasonable and orderly management model, and clarified the management system, method and comprehensive management process. CONCLUSION: The problems, principles and models of donated drugs management were sorted out comprehensively, which is helpful to prevent and control of coronavirus disease 2019 (COVID-19).","PeriodicalId":22409,"journal":{"name":"The Chinese Pharmaceutical Journal","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89684865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-02-22DOI: 10.11669/CPJ.2017.04.008
L. Cao, Tao Liu, Zhuo-Jia Chen, S. Jia, B. Huang, Hong-Bing Huang
{"title":"Investigation the importance of serglycinin the drug-resistance to the doxorubicin in breast cancer","authors":"L. Cao, Tao Liu, Zhuo-Jia Chen, S. Jia, B. Huang, Hong-Bing Huang","doi":"10.11669/CPJ.2017.04.008","DOIUrl":"https://doi.org/10.11669/CPJ.2017.04.008","url":null,"abstract":"","PeriodicalId":22409,"journal":{"name":"The Chinese Pharmaceutical Journal","volume":"14 1","pages":"284-287"},"PeriodicalIF":0.0,"publicationDate":"2017-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91093723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-11-22DOI: 10.11669/CPJ.2016.22.006
Baoping Zhou, Chunlei Zhang, Xiaoqing Zou, Jian Xu, Yan Li, Xichun Li, Chengzhi Chai, Zhengyu Cao
OBJECTIVE: To investigate the chemical constituents of the aerial parts of Ribes diacanthum Pall. METHODS: The compounds were isolated and purified by silica gel, Sephadex LH-20 colunm chromatography and HPLC. The structures were elucidated on the basis of spectral data and physiochemical properties. RESULTS: Nineteen compounds were isolated from 95% ethanol extracts and identified as quercetin (1), quercetin-3-O-β-D-glucopyranoside (2), quercetin-3-O-α-L-rhamnopyranoside (3), quercetin-3-O-β-D-neohesperoside (4), mearnsetin (5), myricetin-3-O-α-L-rhamnoside (6), myricetin-3-O-β-D-glucopyranoside (7), mearnsetin 3-O-β-D-glucopyranoside (8), mearnsetin 3-O-α-L-rhamnopyranoside (9), kaempferol-3-O-β-D-glucopyranoside (10), kaempferol 3-O-β-D-(2-O-α-L-rhamnopyranosyl) glucopyranoside (11), kaempferol 3-(2'', 6''-di-O-α-L-rhamnosyl)-β-D-glucoside (12), 1, 2, 4-trihydroxybenzene (13), vanillic acid (14), protocatechuic acid (15), 4-hydroxy benzoic acid (16), gallic acid (17), blumenol C glucoside (18), conocarpan (19). CONCLUSION: All the compounds are isolated from the title plant and the NMR data for 8 is reported here for the first time.
目的:研究白刺地上部的化学成分。方法:采用硅胶、Sephadex LH-20柱层析和高效液相色谱法对化合物进行分离纯化。根据光谱数据和理化性质对其结构进行了鉴定。结果:19化合物- 95%乙醇提取物中分离鉴定为槲皮素(1)quercetin-3-O -β-D-glucopyranoside (2), quercetin-3-O -α-L-rhamnopyranoside (3), quercetin-3-O -β-D-neohesperoside (4), mearnsetin (5), myricetin-3-O -α-L-rhamnoside (6), myricetin-3-O -β-D-glucopyranoside (7), mearnsetin 3 -β-D-glucopyranoside (8), mearnsetin 3点-α-L-rhamnopyranoside (9), kaempferol-3-O -β-D-glucopyranoside(10)、山柰酚3 -β- d - (2 o -α-L-rhamnopyranosyl)吡喃葡萄糖苷(11),山奈酚3-(2′，6′-二- o -α- l -鼠李糖基)-β- d -葡萄糖苷(12)、1,2,4 -三羟基苯(13)、香草酸(14)、原儿茶酸(15)、4-羟基苯甲酸(16)、没食子酸(17)、蓝薄荷醇C -葡萄糖苷(18)、康康康(19)。结论:所有化合物均从该植物中分离得到，其中8个化合物的NMR数据为首次报道。
{"title":"Chemical constituents from the aerial parts of ribes diacanthum pall","authors":"Baoping Zhou, Chunlei Zhang, Xiaoqing Zou, Jian Xu, Yan Li, Xichun Li, Chengzhi Chai, Zhengyu Cao","doi":"10.11669/CPJ.2016.22.006","DOIUrl":"https://doi.org/10.11669/CPJ.2016.22.006","url":null,"abstract":"OBJECTIVE: To investigate the chemical constituents of the aerial parts of Ribes diacanthum Pall. METHODS: The compounds were isolated and purified by silica gel, Sephadex LH-20 colunm chromatography and HPLC. The structures were elucidated on the basis of spectral data and physiochemical properties. RESULTS: Nineteen compounds were isolated from 95% ethanol extracts and identified as quercetin (1), quercetin-3-O-β-D-glucopyranoside (2), quercetin-3-O-α-L-rhamnopyranoside (3), quercetin-3-O-β-D-neohesperoside (4), mearnsetin (5), myricetin-3-O-α-L-rhamnoside (6), myricetin-3-O-β-D-glucopyranoside (7), mearnsetin 3-O-β-D-glucopyranoside (8), mearnsetin 3-O-α-L-rhamnopyranoside (9), kaempferol-3-O-β-D-glucopyranoside (10), kaempferol 3-O-β-D-(2-O-α-L-rhamnopyranosyl) glucopyranoside (11), kaempferol 3-(2'', 6''-di-O-α-L-rhamnosyl)-β-D-glucoside (12), 1, 2, 4-trihydroxybenzene (13), vanillic acid (14), protocatechuic acid (15), 4-hydroxy benzoic acid (16), gallic acid (17), blumenol C glucoside (18), conocarpan (19). CONCLUSION: All the compounds are isolated from the title plant and the NMR data for 8 is reported here for the first time.","PeriodicalId":22409,"journal":{"name":"The Chinese Pharmaceutical Journal","volume":"1 1","pages":"1918-1922"},"PeriodicalIF":0.0,"publicationDate":"2016-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90092955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-09-22DOI: 10.11669/CPJ.2016.18.009
P. Lu, Dafei Xu, Qi Wu, Yue Wang, Ai-ping Wang, Z. Wang, Y. Zeng, Z. Zhuang
{"title":"Research of protein phosphatase 2A inhibition by norcantharidin on radiosensitivity enhancement of nasopharyngeal carcinoma CNE1","authors":"P. Lu, Dafei Xu, Qi Wu, Yue Wang, Ai-ping Wang, Z. Wang, Y. Zeng, Z. Zhuang","doi":"10.11669/CPJ.2016.18.009","DOIUrl":"https://doi.org/10.11669/CPJ.2016.18.009","url":null,"abstract":"","PeriodicalId":22409,"journal":{"name":"The Chinese Pharmaceutical Journal","volume":"46 1","pages":"1579-1585"},"PeriodicalIF":0.0,"publicationDate":"2016-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79346272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：